Neo-TILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple Negative Breast Cancer (TNBC) Patients with Elevated Tumor-Infiltrating Lymphocytes (TILs)
- Sponsor:
- MUSC
- Sponsor Study ID:
- 104044
- CTO #:
- 104044
- NCT Number:
- NCT07743190
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To evaluate whether the pathologic complete response (pCR) rate achieved with a 12 week neoadjuvant carboplatin paclitaxel pembrolizumab (CPP) regimen in patients with high TIL early stage TNBC is not inferior to the historical pCR rate observed with the Keynote 522 regimen.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu
- Study Coordinator, Dawson, Jake, at dawsojak@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina